Core Insights - Roche announced new data from the AVONELLE-X and SALWEEN studies of Vabysmo, demonstrating its efficacy and safety in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) [1][4][8] Group 1: Study Findings - The AVONELLE-X study showed that nearly 80% of nAMD patients extended their treatment intervals to every three or four months after up to four years of treatment with Vabysmo [1][4] - In the SALWEEN study, patients with PCV experienced a clinically meaningful gain of 8.9 letters in best-corrected visual acuity (BCVA) from baseline, with over 60% of patients showing complete resolution of abnormal lesions [1][4][7] - Vabysmo was well tolerated in both studies, with a safety profile consistent with its known safety in nAMD [1][4] Group 2: Disease Context - nAMD is a leading cause of vision loss, affecting around 20 million people globally, particularly those over 60 years old [2][3] - PCV is a subtype of nAMD, more prevalent in Asian populations, accounting for up to 60% of nAMD cases in this demographic [3][4] Group 3: Product Information - Vabysmo is the first bispecific antibody approved for eye conditions, targeting angiopoietin-2 and vascular endothelial growth factor-A to stabilize blood vessels [8][11] - The drug is approved in over 100 countries for nAMD and diabetic macular edema, with more than eight million doses distributed globally since its US approval in 2022 [1][8]